Galadari I, Rubaie S, Alkaabi J, Galadari H
Faculty of Medicine and Health Sciences, UAE University, Dermatology Department, Al-Ain Hospital, Al-Ain, UAE.
Eur Ann Allergy Clin Immunol. 2003 Dec;35(10):397-401.
Diphenylcyclopropenone (DPCP) has been reported to be an effective topical immunotherapy of extensive alopecia areata (AA) with highly variable reported results.
The purposes of this study were to assess the efficacy, side effects, and adverse prognostic factors in the treatment of alopecia areata with DPCP.
21 patients were included in the study with chronic and extensive AA. Patients were sensitized in the beginning with 2% DPCP, and the concentrations were increased gradually beginning with 0.000001% every one to two weeks for a period of 6 months.
15 patients (71.4%) had a complete or partial recovery at the end of the treatment period. Most frequent side effects were erythema at the site of application, pigmentation, and lymph node enlargement. The most important adverse prognostic factors were duration of AA, history of atopy, and presence of nail changes.
Treatment of AA with topical DPCP is effective. Though the treatment may have some side effects, in most cases they are tolerable and respond well to treatment.
据报道，二苯环丙烯酮（DPCP）是广泛斑秃（AA）的一种有效的局部免疫疗法，但其报道结果差异很大。
本研究旨在评估DPCP治疗斑秃的疗效、副作用及不良预后因素。
本研究纳入21例慢性广泛性AA患者。患者开始时用2% DPCP致敏，随后浓度从0.000001%开始，每1至2周逐渐增加，持续6个月。
15例患者（71.4%）在治疗期结束时完全或部分恢复。最常见的副作用是用药部位红斑、色素沉着和淋巴结肿大。最重要的不良预后因素是斑秃持续时间、特应性病史和甲改变的存在。
外用DPCP治疗斑秃有效。虽然该治疗可能有一些副作用，但在大多数情况下是可耐受的，且对治疗反应良好。
